xRead Articles - October 2022

(Continues)

24-hr and nighttime cough frequency (coughs/hr) CQLQ

Cough global rating of change Capsaicin and ATP cough challenge Urge-to-cough VAS

24-hr cough frequency (coughs/hr)

Overall symptom severity Perceived degree (%) of symptom change

Cough frequency (coughs/hr) Daytime cough frequency (coughs/hr)

24-hr and nighttime cough frequency (coughs/hr) LCQ

8 weeks LCQ Cough severity score FeNO

Cough severity VAS

Urge-to-cough VAS

Cough severity VAS LCQ Cough symptom score

Capsaicin cough challenge GerdQ Cough severity VAS

Cough severity VAS

Urge-to-cough VAS LCQ

Capsaicin cough challenge LCQ

Cough global rating of change

Urge-to-cough VAS HARQ

Cough severity VAS PFTs FeNO HARQ LCQ

8 weeks Modi fi ed RSI VHI-10

Sputum examination PFTs FeNO

Cough severity VAS

Cough global rating of change

2 weeks Daytime cough frequency

(coughs/hr)

Single dose Daytime cough frequency

(coughs/hr)

cough resolution

12 weeks Daytime cough frequency

(coughs/hr)

2 weeks Daytime cough frequency

(coughs/hr)

Single dose Capsaicin, ATP, citric acid, distilled water cough challenges

2 weeks Daytime cough frequency

(coughs/hr)

2 weeks 24-hour cough frequency

(coughs/hr)

2 weeks 24-hr cough frequency

(coughs/hr)

12 weeks Daytime cough frequency

(coughs/hr)

12 weeks Successful rate of

Neuromodulator : gabapentin

oral tablet daily for 3 days, then TID for remainder of treatment period (21) Placebo oral tablet BID

900 mg daily (117)

Placebo

oral tablet

Placebo

oral tablet BID

prednisolone 20 mg daily (15) Placebo

oral tablet daily (93)

Placebo

Placebo

oral tablet

Placebo

oral tablet daily (15) Placebo

inhaler TID

Placebo

oral tablet BID (12) Placebo

Oral corticosteroid

oral tablet BID (63)

Belvisi et al (2017) London, England, UK Crossover RCT 20; 18 (5/15) 63.1 TRPV-1 inhibitor : XEN-D0501 4 mg BID Jang et al (2017) Boston, MA, USA Parallel RCT 30; 19 (11/7) E: 42 C: 49 Tricyclic antidepressant : amitriptyline 12.5 mg qHS, maximum 50 mg daily (15)

Birring et al (2017) London, England, UK Crossover RCT 28; 27 (6/21) 62 Mast cell inhibitor : sodium cromoglicate (PA101) 40 mg/inhalation TID Sadeghi et al (2018) Cottingham, England, UK Parallel RCT 50; 47 (17/32) 62 Leukotriene antagonist : montelukast 10 mg qHS (35) NCT03282591 (2018) UK, USA Parallel RCT 185; 176 (41/135) E: 62.7 C: 62.6 NK-1 inhibitor : serlopitant 5 mg daily (92) Dong et al (2019) Shanghai, China Parallel RCT 234; 217 (89/145) E: 45.2 C: 47.5 Neuromodulator : baclofen

NCT02397460 (2015) UK Crossover RCT 24; 24 (sex NR) NR P2X3 inhibitor : AF-219 50 mg (12 patients), AF-219 300 mg (12 patients) Hodgson et al (2016) Nottingham, England, UK Parallel RCT 44; 20 (14/30) E: 59.6 C: 56.9 Macrolide antibiotic :

Crossover RCT 24; 18 (6/18) 54.5 P2X3 inhibitor : AF-219 600 mg BID

61 P2X3 inhibitor : gefapixant 100 mg

P2X3 inhibitor : gefapixant

Smith et al (2020) Manchester, England, UK Parallel RCT 253; 222 (60/193) 60.2 P2X3 inhibitor : gefapixant 7.5 mg BID (64)

azithromycin 500 mg daily

for 3 days, then 250 mg TID for remainder of treatment period (21)

60 mg daily (117)

45 mg BID (11)

20 mg BID (63)

50 mg BID (63)

E: 54.5

C: 57.2

NCT03482713 (2019) Japan Parallel RCT 23; 23 (6/17)

(3/21)

Crossover RCT 24; 24

England, UK

Morice et al (2019) Cottingham, England, UK

Manchester,

Abdulqawi et al (2015)

Laryngoscope 132: January 2022

Wamkpah et al.: Multimodal Treatments for Neurogenic Cough 111